CARCINOMA, RENAL CELL

This early-stage study tests a new drug called KFA115, alone or with pembrolizumab, in people with advanced cancers like lung, skin, kidney, and others. The main goal is to find the safest dose and understand side effects. About 126 participants will be enrolled to see if the tre…

This study tests whether adding either belzutifan or quavonlimab to a standard two-drug therapy (pembrolizumab and lenvatinib) helps people with advanced clear cell renal cell carcinoma live longer or keep their cancer from growing. About 1,650 adults who have not had prior treat…

This phase 3 trial tests whether a new drug combination (belzutifan + lenvatinib) works better than the current standard drug (cabozantinib) for people with advanced kidney cancer that has gotten worse after prior treatment. About 747 participants will be enrolled. The study meas…

This study tests a new drug called savolitinib against a standard treatment (sunitinib) for people with a rare, advanced kidney cancer called MET-driven papillary renal cell carcinoma. The goal is to see if savolitinib works better at slowing cancer growth and has fewer side effe…

This phase 3 study tests whether adding belzutifan (a pill) to standard pembrolizumab (an IV drug) can better prevent kidney cancer from returning after surgery. About 1,800 adults with clear cell renal cell carcinoma at intermediate-high or high risk of recurrence will receive e…

This study tests if adding a new drug (belzutifan) or a different immunotherapy combo (MK-1308A) to standard treatment helps people with advanced clear cell kidney cancer live longer or slow their cancer. About 249 Chinese adults who have not had prior treatment for advanced dise…

This study tests experimental drug combinations for people with advanced clear cell renal cell carcinoma (a type of kidney cancer) who have not received prior treatment. The goal is to check safety and how well the combinations shrink tumors. About 400 participants will be enroll…

This study is for people with advanced kidney cancer that has gotten worse after initial treatment. It tests new combinations of drugs to see if they are safe and can shrink tumors. About 370 participants will receive experimental treatments, and researchers will monitor side eff…

This study aims to understand how the immune system changes in people with kidney or bladder cancer when they receive immunotherapy. Researchers will measure different immune cells and tumor cells in the blood before and during treatment. The goal is to learn more about how these…